Thrivelab: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of Thrivelab's website, https://www.thrivelab.com, FDA Establishment Identifier (FEI) 3043997633, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide products.

1. 1

   “1. The compounded semaglutide products displayed on your website identify “thrivelab” on the pictured label, suggesting Thrivelab is the compounder of those drugs when in fact it is not.”

2. 2

   ““Same active ingredient as Ozempic®” “Same active ingredient as Wegovy and Ozempic” “clinically proven to work””

3. 3

   “Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

thrivelab.com returned a live storefront when we checked in August 2026, still listing a semaglutide weight-loss programme alongside hormone therapy, peptides, nutrition coaching and virtual primary care, and promoting insurance-based cost reduction.

It is tempting to read the personal address as a sign FDA took this case more seriously than the others, and there is nothing in the letter that supports that reading — the findings are the mildest kind in the collection, two same-ingredient lines and a four-word efficacy phrase. Who a letter is addressed to is a clerical fact, not a measure of severity, and treating it as one is precisely the mistake these pages exist to prevent. What is worth carrying into a price comparison here is smaller and specific: the compounded semaglutide sits in a catalogue with hormone therapy, coaching and primary care, sold partly on insurance savings, and FDA's finding is that the vial's branding identifies a seller rather than a compounder. The cost of a bundle tells you nothing about who made the one prescription drug inside it.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Thrivelab failed to respond.